Biocartis Group NV

Biocartis to host webcast for announcement 2016 financial results on 2 March 2017

PRESS RELEASE: REGULATED INFORMATION  
23 February 2017, 07:00 CET

BioCARTIS to Host Webcast FOR ANNOUNCEMENT 2016 Financial Results on 2 March 2017

Mechelen, Belgium, 23 February 2017 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company, today announces that it will host a live webcast on Thursday, 2 March 2017 at 14:00 CET / 13:00 BST (UK) / 08:00 EDT (US) to announce its 2016 results and 2017 outlook.

The live webcast may be accessed on the Biocartis website or by clicking here. To participate in the questions and answers session, please dial in 5-10 minutes prior to the start time using the numbers below, followed by the confirmation code 9539312. The webcast and conference call will be conducted in English. A replay of the webcast will be available on the Biocartis website ('investors') shortly after.

Conference call dial-ins:

• London, United Kingdom (standard international):                      [phone]
• Brussels, Belgium:                                                                   [phone]
• Amsterdam, Netherlands:                                                         [phone]
• New York, USA:                                                                       [phone]
• Paris, France:                                                                          [phone]

Confirmation code:  9539312

----- END ----

More information:

Renate Degrave
Manager Corporate Communications & Investor Relations
e-mail    [e-mail]
tel         [phone]
mobile   [phone]

About Biocartis 
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers seven oncology tests and two infectious disease tests. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.